Skip to main content

Intelence FDA Approval History

FDA Approved: Yes (First approved January 18, 2008)
Brand name: Intelence
Generic name: etravirine
Dosage form: Tablets
Previous Name: TMC125
Company: Johnson & Johnson Innovative Medicine
Treatment for: HIV Infection

Intelence (etravirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Development timeline for Intelence

DateArticle
Mar 27, 2012Approval FDA Approves Intelence (etravirine) Tablets for Treatment-Experienced Pediatric Patients with HIV-1, Following Priority Review
Jan  3, 2011Approval FDA Approves New Dosage Strength for Intelence
Dec  2, 2009Approval U.S. Food And Drug Administration (FDA) Grants Traditional Approval for Intelence (etravirine)
Jan 22, 2008Approval FDA Approves Intelence (etravirine) for HIV Combination Therapy
Sep 20, 2007FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
Jul 18, 2007New Drug Application for Investigational HIV Treatment TMC125 Submitted to U.S. Food and Drug Administration

See also

Intelence (etravirine) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer